Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders

Blood Reviews

Volumn 19, Issue 1, 2005, Pages 1-13

  Kralovics, Robert ^a   Skoda, Radek C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

c MPL; Erythropoietin; Essential thrombocythemia; Herditary MPD; Idiopahtic myelofibrosis; Loss of heterozygosity; Myeloproliferative disorders; Polycythemia vera; PRV 1; Thrombopoietin

Indexed keywords

CYTOKINE; THROMBOPOIETIN RECEPTOR;

CHROMOSOME; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLONAL VARIATION; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; HEMATOPOIESIS; HEREDITY; HETEROZYGOSITY; HUMAN; IN VITRO STUDY; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PEDIGREE; PHENOTYPE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; STEM CELL; THROMBOCYTHEMIA; THROMBOCYTOSIS; UNITED STATES;

EID: 9644275709     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2004.02.002     Document Type: Article

References (121)

1. Randi M.L., Stocco F., Rossi C., Tison T., Girolami A. Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J. Med. 22:1991;213-223
2. Murphy S. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb. Haemost. 78:1997;622-626
3. Sterkers Y., Preudhomme C., Lai J.L., Demory J.L., Caulier M.T., Wattel E., et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 91:1998;616-622
4. Shibata K., Shimamoto Y., Suga K., Sano M., Matsuzaki M., Yamaguchi M. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation - a brief review of recent literature. Acta Haematol. 91:1994;84-88
5. Murphy S., Peterson P., Iland H., Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 34:1997;29-39
6. Damashek W. Some speculations on the myeloproliferative syndromes. Blood. 6:1951;372
7. Correa P., Eskinazi D., Axelrad A. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor I in vitro: studies in an improved serum-free medium. Blood. 83:1994;99-112
8. Dai C.H., Krantz S.B., Means R.T., Horn S.T., Gilbert H.S. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J. Clin. Invest. 87:1991;391-396
9. Dai C.H., Krantz S.B., Dessypris E.N., Means R.T., Horn S.T., Gilbert H.S. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood. 80:1992;891-899
10. Prchal J.F., Axelrad A.A. Letter: Bone-marrow responses in polycythemia vera. N. Engl. J. Med. 290:1974;1382
11. Weinberg R.S. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin. Hematol. 34:1997;64-69
12. Kralovics R., Prchal J.T. Haematopoietic progenitors and signal transduction in polycythaemia vera and primary thrombocythaemia. Baillieres Clin. Haematol. 11:1998;803-818
13. Weinberg R.S., Worsley A., Gilbert H.S., Cuttner J., Berk P.D., Alter B.P. Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies. Leuk. Res. 13:1989;331-338
14. Kralovics R., Buser A.S., Teo S.S., Coers J., Tichelli A., Van Der Maas A.P., et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 102:2003;1869-1871
15. Zwicky C., Theiler L., Zbaren K., Ischi E., Tobler A. The predictive value of clonogenic stem cell assays for the diagnosis of polycythaemia vera. Br. J. Haematol. 117:2002;598-604
16. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 100:2002;2292-2302
17. Shih L.Y., Lee C.T. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood. 83:1994;744-748
18. Thiele J., Kvasnicka H.M. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann. Hematol. 82:2003;148-152
19. Li Y., Hetet G., Maurer A.M., Chait Y., Dhermy D., Briere J. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Br. J. Haematol. 87:1994;471-476
20. Rolovic Z., Basara N., Gotic M., Sefer D., Bogdanovic A. The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis. Br. J. Haematol. 90:1995;326-331
21. Axelrad A.A., Eskinazi D., Correa P.N., Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 96:2000;3310-3321
22. Le Couedic J.P., Mitjavila M.T., Villeval J.L., Feger F., Gobert S., Mayeux P., et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood. 87:1996;1502-1511
23. Mirza A.M., Correa P.N., Axelrad A.A. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera. Blood. 86:1995;877-882
24. Horikawa Y., Matsumura I., Hashimoto K., Shiraga M., Kosugi S., Tadokoro S., et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood. 90:1997;4031-4038
25. Shultz L.D., Schweitzer P.A., Rajan T.V., Yi T., Ihle J.N., Matthews R.J., et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell. 73:1993;1445-1454
26. Asimakopoulos F.A., Hinshelwood S., Gilbert J.G., Delibrias C.C., Gottgens B., Fearon D.T., et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene. 14:1997;1215-1222
27. Andersson P., LeBlanc K., Eriksson B.A., Samuelsson J. No evidence for an altered mRNA expression or protein level of haematopoietic cell phosphatase in CD34+ bone marrow progenitor cells or mature peripheral blood cells in polycythaemia vera. Eur. J. Haematol. 59:1997;310-317
28. Silver R.T. Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera. Leukemia. 17:2003;1186-1187
29. Oehler L, Jaeger E, Eser A, Sillaber C, Gisslinger H, Geissler K. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. Blood 2003 [prepublished on-line]
30. Sui X., Krantz S.B., Zhao Z. Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells. Blood. 90:1997;651-657
31. Xu M.J., Sui X., Zhao R., Dai C., Krantz S.B., Zhao Z.J. PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood. 102:2003;4354-4360
32. Gu M., Warshawsky I., Majerus P.W. Cloning and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to retinaldehyde-binding protein and yeast SEC14p. Proc. Natl. Acad. Sci. USA. 89:1992;2980-2984
33. Kawada E., Tamura J., Kubota K., Murakami H., Naruse T., Tsuchiya J. Possible involvement of protein kinase C in the aberrant regulation of erythropoiesis in polycythemia vera. Leuk. Res. 21:1997;101-105
34. Roder S., Steimle C., Meinhardt G., Pahl H.L. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp. Hematol. 29:2001;694-702
35. Moliterno A.R., Hankins W.D., Spivak J.L. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N. Engl. J. Med. 338:1998;572-580
36. Harrison C.N., Gale R.E., Pezella F., Mire-Sluis A., MacHin S.J., Linch D.C. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. Br. J. Haematol. 107:1999;139-147
37. Le Blanc K., Andersson P., Samuelsson J. Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera. Br. J. Haematol. 108:2000;80-85
38. Westwood N.B., Raj K., Messinezy M., Pearson T.C. Platelet expression of Mpl is diminished in reactive thrombocytosis and in myeloproliferative disorders but is normal in secondary erythrocytosis. Blood. 94(Suppl. 1):1999;491
39. Wiestner A., Schlemper R.J., van der Maas A.P., Skoda R.C. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat. Genet. 18:1998;49-52
40. Temerinac S., Klippel S., Strunck E., Roder S., Lubbert M., Lange W., et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood. 95:2000;2569-2576
41. Klippel S., Strunck E., Busse C.E., Behringer D., Pahl H.L. Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. Blood. 100:2002;2441-2448
42. Kissel K., Santoso S., Hofmann C., Stroncek D., Bux J. Molecular basis of the neutrophil glycoprotein NB1 (CD177) involved in the pathogenesis of immune neutropenias and transfusion reactions. Eur. J. Immunol. 31:2001;1301-1309
43. Wolff J., Brendel C., Fink L., Bohle R.M., Kissel K., Bux J. Lack of NB1 GP (CD177/HNA-2a) gene transcription in NB1 GP-neutrophils from NB1 GP-expressing individuals and association of low expression with NB1 gene polymorphisms. Blood. 102:2003;731-733
44. Spinelli O., Rota B., Finazzi G., Barbui T., Rambaldi A. Quantitative analysis of PRV-1 gene expression in chronic myeloproliferative disorders: positive correlation with polycythemia vera diagnosis and leukocyte alkaline phosphatase expression. Blood. 100(Suppl. 1):2002;3145a
45. Liu E., Jelinek J., Pastore Y.D., Guan Y., Prchal J.F., Prchal J.T. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 101:2003;3294-3301
46. Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, et al. Quantification of PRV-1 mRNA distinguishes Polycythemia vera from secondary erythrocytosis. Blood 2003 [prepublished on-line]
47. Johansson P., Andreasson B., Safai_Kutti S., Wennstrom L., Palmqvist L., Ricksten A., et al. The presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia. Eur. J. Haematol. 70:2003;358-362
48. Silva M., Richard C., Benito A., Sanz C., Olalla I., Fernandez-Luna J.L. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N. Engl. J. Med. 338:1998;564-571
49. Giraudier S., Chagraoui H., Komura E., Barnache S., Blanchet B., LeCouedic J.P., et al. Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood. 100:2002;2932-2940
50. Westwood N.B., Gilbert H.L., Pearson T.C. Circulating CD34(+) cells in polycythemia vera are present in normal concentration, do not exhibit constitutive apoptosis and express normal levels of CD95, and Bcl-2 related proteins. Blood. 92(Suppl. 1):1998;4110
51. Kralovics R., Guan Y., Prchal J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. 30:2002;229-236
52. Adamson J.W., Fialkow P.J., Murphy S., Prchal J.F., Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N. Eng. J. Med. 295:1976;913-916
53. Fialkow P.J., Faguet G.B., Jacobson R.J., Vaidya K., Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 58:1981;916-918
54. El-Kassar N., Hetet G., Briere J., Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood. 89:1997;128-134
55. Anger B., Janssen J.W., Schrezenmeier H., Hehlmann R., Heimpel H., Bartram C.R. Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia. 4:1990;258-261
56. Kreipe H., Jaquet K., Felgner J., Radzun H.J., Parwaresch M.R. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood. 78:1991;1814-1817
57. Harrison C.N., Gale R.E., Machin S.J., Linch D.C. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 93:1999;417-424
58. Rege-Cambrin G., Mecucci C., Tricot G., Michaux J.L., Louwagie A., Van Hove W., et al. A chromosomal profile of polycythemia vera. Cancer Genet. Cytogenet. 25:1987;233-245
59. Diez-Martin J.L., Graham D.L., Petitt R.M., Dewald G.W. Chromosome studies in 104 patients with polycythemia vera. Mayo Clinic Proc. 66:1991;287-299
60. Mertens F., Johansson B., Heim S., Kristoffersson U., Mitelman F. Karyotypic patterns in chronic myeloproliferative disorders: report on74 cases and review of the literature. Leukemia. 5:1991;214-220
61. Reilly J.T., Snowden J.A., Spearing R.L., Fitzgerald P.M., Jones N., Watmore A., et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br. J. Haematol. 98:1997;96-102
62. Kanfer E., Price C.M., Colman S.M., Barrett A.J. Erythropoietin- independent colony growth in polycythaemia vera is not restricted to progenitor cells with trisomy of chromosome 8. Br. J. Haematol. 82:1992;773-774
63. Asimakopoulos F.A., Gilbert J.G., Aldred M.A., Pearson T.C., Green A.R. Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera. Blood. 88:1996;2690-2698
64. Westwood N.B., Gruszka_Westwood A.M., Pearson C.E., Delord C.F., Green A.R., Huntly B.J., et al. The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization. Br. J. Haematol. 110:2000;839-846
65. Najfeld V., Montella L., Scalise A., Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br. J. Haematol. 119:2002;558-566
66. Asimakopoulos F.A., White N.J., Nacheva E., Green A.R. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood. 84:1994;3086-3094
67. Bench A.J., Aldred M.A., Humphray S.J., Champion K.M., Gilbert J.G., Asimakopoulos F.A., et al. A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region. Genomics. 49:1998;351-362
68. Bench A.J., Nacheva E.P., Hood T.L., Holden J.L., French L., Swanton S., et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene. 19:2000;3902-3913
69. Chen Z., Notohamiprodjo M., Guan X.Y., Paietta E., Blackwell S., Stout K., et al. Gain of 9p in the pathogenesis of polycythemia vera. Genes Chromosom. Cancer. 22:1998;321-324
70. Westwood N.B., Gruszka_Westwood A.M., Atkinson S., Pearson T.C. Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization. Haematologica. 86:2001;464-469
71. Bentz M., Barth T.F., Bruderlein S., Bock D., Schwerer M.J., Baudis M., et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosom. Cancer. 30:2001;393-401
72. Ang S.O., Chen H., Hirota K., Gordeuk V.R., Jelinek J., Guan Y., et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet. 32:2002;614-621
73. Stuhrmann M., Bashawri L., Ahmed M.A., Al-Awamy B.H., Kuhnau W., Schmidtke J., et al. Familial thrombocytosis as a recessive, possibly X-linked trait in an Arab family. Br. J. Haematol. 112:2001;616-620
74. Cazzola M., Skoda R.C. Translational pathophysiology: a novel molecular mechanism of human disease. Blood. 95:2000;3280-3288
75. Harrison C.N., Gale R.E., Wiestner A.C., Skoda R.C., Linch D.C. The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Br. J. Haematol. 102:1998;1341-1343
76. Komatsu H., Ding J., Iida M., Ito M., Kato-Uranishi M., Sanda T., et al. Familial essentian thrombocythemia associated with a dominant positive acting mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 102:2003;29
77. Kunishima S., Mizuno S., Naoe T., Saito H., Kamiya T. Genes for thrombopoietin and c-mpl are not responsible for familial thrombocythaemia: a case study. Br. J. Haematol. 100:1998;383-386
78. Wiestner A., Padosch S.A., Ghilardi N., Cesar J.M., Odriozola J., Shapiro A., et al. Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br. J. Haematol. 110:2000;104-109
79. Taksin A.L., Couedic J.P., Dusanter_Fourt I., Masse A., Giraudier S., Katz A., et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood. 93:1999;125-139
80. Juvonen E., Ikkala E., Fyhrquist F., Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood. 78:1991;3066-3069
81. Kralovics R., Indrak K., Stopka T., Berman B.W., Prchal J.F., Prchal J.T. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood. 90:1997;2057-2061
82. Kralovics R., Prchal J.T. Genetic heterogeneity of primary familial and congenital polycythemia. Am. J. Hematol. 68:2001;115-121
83. Hess G., Rose P., Gamm H., Papadileris S., Huber C., Seliger B. Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br. J. Haematol. 88:1994;794-802
84. Ang S.O., Chen H., Gordeuk V.R., Sergueeva A.I., Polyakova L.A., Miasnikova G.Y., et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol. Dis. 28:2002;57-62
85. Pastore Y., Jedlickova K., Guan Y., Liu E., Fahner J., Hasle H., et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am. J. Hum. Genet. 73:2003;412-419
86. Percy M.J., McMullin M.F., Jowitt S.N., Potter M., Treacy M., Watson W.H., et al. Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood. 102:2003;1097-1099
87. Pastore Y.D., Jelinek J., Ang S., Guan Y., Liu E., Jedlickova K., et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood. 101:2003;1591-1595
88. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:2002;673-682
89. Kim W., Kaelin W.G. Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13:2003;55-60
90. Kralovics R., Stockton D.W., Prchal J.T. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 102:2003;3793-3797
91. Perez-Encinas M, Bello JL, Perez-Crespo S, De Miguel R, Tome S. Familial myeloproliferative syndrome. Am J Hematol 1994;46:225-229
92. Eridani S., Sawyer B., Pearson T.C. Patterns of in vitro BFU-E proliferation in different forms of polycythaemia and in thrombocythaemia. Eur. J. Haematol. 38:1987;363-369
93. Juvonen E., Ikkala E., Oksanen K., Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br. J. Haematol. 83:1993;192-197
94. Lutton J.D., Levere R.D. Endogenous erythroid colony formation by peripheral blood mononuclear cells from patients with myelofibrosis and polycythemia vera. Acta Haematol. 62:1979;94-99
95. Lemoine F., Najman A., Baillou C., Stachowiak J., Boffa G., Aegerter P., et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood. 68:1986;996-1002
96. Montagna C., Massaro P., Morali F., Foa P., Maiolo A.T., Eridani S. In vitro sensitivity of human erythroid progenitors to hemopoietic growth factors: studies on primary and secondary polycythemia. Haematologica. 79:1994;311-318
97. Kimura H., Ohkoshi T., Matsuda S., Uchida T., Kariyone S. Megakaryocytopoiesis in polycythemia vera: characterization by megakaryocytic progenitors (CFU-Meg) in vitro and quantitation of marrow megakaryocytes. Acta Haematol. 79:1988;1-6
98. Battegay E.J., Thomssen C., Nissen C., Gudat F., Speck B. Endogenous megakaryocyte colonies from peripheral blood in precursor cell cultures of patients with myeloproliferative disorders. Eur. J. Haematol. 42:1989;321-326
99. Florensa L., Besses C., Almarcha J., Lafuente R., Palou L., Pedro C., et al. Circulating erythroid and megakaryocytic progenitors in polycythaemia vera and essential thrombocythaemia. Eur. J. Haematol. 43:1989;417-422
100. Juvonen E., Partanen S., Ruutu T. Colony formation by megakaryocytic progenitors in essential thrombocythaemia. Br. J. Haematol. 66:1987;161-164
101. Kimura H., Ishibashi T., Sato T., Matsuda S., Uchida T., Kariyone S. Megakaryocytic colony formation (CFU-Meg) in essential thrombocythemia: quantitative and qualitative abnormalities of bone marrow CFU-Meg. Am. J. Hematol. 24:1987;23-30
102. Mazur E.M., Cohen J.L., Bogart L. Growth characteristics of circulating hematopoietic progenitor cells from patients with essential thrombocythemia. Blood. 71:1988;1544-1550
103. Han Z.C., Briere J., Nedellec G., Abgrall J.F., Sensebe L., Parent D., et al. Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis. Eur. J. Haematol. 40:1988;130-135
104. ′ -untranslated region of the thrombopoietin gene Blood. 92:1998;1091-1096
105. Ghilardi N., Skoda R.C. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocytosis through a mechanism of more efficient translation of TPO mRNA [letter]. Blood. 94:1999;1480-1482
106. Ghilardi N., Wiestner A., Kikuchi M., Oshaka A., Skoda R.C. Hereditary thrombocythemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br. J. Haematol. 107:1999;310-316
107. Jorgensen M.J., Raskind W.H., Wolff J.F., Bachrach H.R., Kaushansky K. Familial thrombocytosis associated with overproduction of thrombopoietin due to a novel splice donor site mutation. Blood. 92(Suppl. 1):1998;205a. (abstract)
108. Fickers M., Speck B. Thrombocythaemia: familial occurrence and transition into blastic crisis. Acta Haematol. 51:1974;257-265
109. Slee P.H.T.J., van Everdingen J.J.E., Geraedts J.P.M., te Velde J., den Ottolander G.J. Familial myeloproliferative disease. Acta Med. Scand. 210:1981;321-327
110. Eyster M.E., Saletan S.L., Rabellino E.M., Karanas A., McDonald T.P., Locke L.A., et al. Familial essential thrombocythemia. Am. J. Med. 80:1986;497-502
111. Ulibarrena C., Vecino A.M., Odriozola J., Cesar J.M. Familial essential thrombocythemia associated with von Willebrand disease (letter; Article in Spanish). Med. Clin. (Barc). 109:1997;237
112. Randi M.L., Fabris F., Vio C., Girolami A. Familial thrombocythemia and/or thrombocytosis - apparently a rare disorder [letter]. Acta Haematol. 78:1987;63
113. Randi M.L., Fabris F., Visentin I., Girolami A. Low incidence of familial occurrence of thrombocythaemia and/or thrombocytosis. Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. 115:1988;695-699
114. Williams E.C., Shahidi N.T. Benign familial thrombocytosis. Am. J. Hematol. 37:1991;124-125
115. Cohen N., Almoznino-Sarafian D., Weissgarten J., Alon I., Zaidenstein R., Dishi V., et al. Benign familial microcytic thrombocytosis with autosomal dominant transmission. Clin. Genet. 52:1997;47-50
116. de la Chapelle A., Träskelin A.L., Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc. Natl. Acad. Sci. USA. 90:1993;4495-4499
117. Furukawa T., Narita M., Sakaue M., Otsuka T., Kuroha T., Masuko M., et al. Primary familial polycythaemia associated with a novel point mutation in the erythropoietin receptor. Br. J. Haematol. 99:1997;222-227
118. Arcasoy M.O., Degar B.A., Harris K.W., Forget B.G. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood. 89:1997;4628-4635
119. Kralovics R., Sokol L., Prchal J.T. Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia. J. Clin. Invest. 102:1998;124-129
120. Watowich S.S., Xie X., Klingmuller U., Kere J., Lindlof M., Berglund S., et al. Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state. Blood. 94:1999;2530-2532
121. Arcasoy M.O., Jiang X., Haroon Z.A. Expression of erythropoietin receptor splice variants in human cancer. Biochem. Biophys. Res. Commun. 307:2003;999-1007